On Monday, Eli Lilly and Co. (LLY.N) announced it would invest $1.6 billion at its two new Indiana manufacturing sites to support the production of Jaypirca, its recently authorized cancer medicine.
Eli Lilly reported $3.7 billion in facility investments.
Lilly has invested $6.4 billion in U.S. manufacturing capacity over the previous three years and expects to ramp up as it prepares to introduce new obesity, Alzheimer’s, and autoimmune disease drugs. Company stated.
In January, the company announced plans to invest $450 million to expand a North Carolina plant to accommodate the demand for its blockbuster diabetic medicine Trulicity and recently introduced Mounjaro. Its North Carolina expansion commitments are $1.7 billion.
